Learn About Amaurosis Fugax

What is the definition of Amaurosis Fugax?

Amaurosis fugax is a temporary loss of vision in one or both eyes due to a lack of blood flow to the retina. The retina is the light-sensitive layer of tissue at the back of the eyeball.

Save information for later
Sign Up
What are the alternative names for Amaurosis Fugax?

Transient monocular blindness; Transient monocular visual loss; TMVL; Transient monocular visual loss; Transient binocular visual loss; TBVL; Temporary visual loss - amaurosis fugax

What are the causes of Amaurosis Fugax?

Amaurosis fugax is not itself a disease. Instead, it is a sign of other disorders. Amaurosis fugax can occur from different causes. One cause is when a blood clot or a piece of plaque blocks an artery in the eye. The blood clot or plaque usually travels from a larger artery, such as the carotid artery in the neck or an artery in the heart, to an artery in the eye.

Plaque is a hard substance that forms when fat, cholesterol, and other substances build up in the walls of arteries. Risk factors include:

  • Heart disease, especially irregular heartbeat
  • Alcohol abuse
  • Cocaine use
  • Diabetes
  • Family history of stroke
  • High blood pressure
  • High cholesterol
  • Increasing age
  • Smoking (people who smoke one pack a day double their risk for a stroke)

Amaurosis fugax can also occur because of other disorders such as:

  • Other eye problems, such as inflammation of the optic nerve (optic neuritis)
  • Blood vessel disease called polyarteritis nodosa
  • Migraine headaches
  • Brain tumor
  • Head injury
  • Multiple sclerosis (MS), inflammation of the nerves due to the body's immune cells attacking the nervous system
  • Systemic lupus erythematosus, an autoimmune disease in which the body's immune cells attack healthy tissue throughout the body
What are the symptoms of Amaurosis Fugax?

Symptoms include the sudden loss of vision in one or both eyes. This usually lasts for a few seconds to several minutes. Afterward, vision returns to normal. Some people describe the loss of vision as a gray or black shade coming down over the eye.

Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for Amaurosis Fugax?

Treatment of amaurosis fugax depends on its cause. When amaurosis fugax is due to a blood clot or plaque, the concern is to prevent a stroke. The following can help prevent a stroke:

  • Avoid fatty foods and follow a healthy, low-fat diet. DO NOT drink more than 1 to 2 alcoholic drinks a day.
  • Exercise regularly: 30 minutes a day if you are not overweight; 60 to 90 minutes a day if you are overweight.
  • Quit smoking.
  • Most people should aim for a blood pressure below 120 to 130/80 mm Hg. If you have diabetes or have had a stroke, your doctor may tell you to aim for a lower blood pressure.
  • If you have diabetes, heart disease, or hardening of the arteries, your LDL (bad) cholesterol should be lower than 70 mg/dL.
  • Follow your doctor's treatment plans if you have high blood pressure, diabetes, high cholesterol, or heart disease.

Your doctor may also recommend:

  • No treatment. You may only need regular visits to check the health of your heart and carotid arteries.
  • Aspirin, warfarin (Coumadin), or other blood-thinning drugs to lower your risk for stroke.

If a large part of the carotid artery appears blocked, carotid endarterectomy surgery is done to remove the blockage. The decision to do surgery is also based on your overall health.

Who are the top Amaurosis Fugax Local Doctors?
Elite
Elite
 
 
 
 
Learn about our expert tiers
Learn more
Elite
What is the outlook (prognosis) for Amaurosis Fugax?

Amaurosis fugax increases your risk for stroke.

When should I contact a medical professional for Amaurosis Fugax?

Contact your provider if any vision loss occurs. If symptoms last longer than a few minutes or if there are other symptoms with the vision loss, seek medical attention right away.

Retina
What are the latest Amaurosis Fugax Clinical Trials?
V-NAV: Advanced Indoor Navigation Aid for Individuals With Visual Impairments, End User Evaluation

Summary: The study will begin with an explanatory/training session where individuals with low vision will learn to use the V-NAV (Vortant NAVigation tool) indoor navigation app, and will have the opportunity to try it for a few representative tasks. The main activity includes a take-home trial, an extended unstructured period to emulate the post-purchase experience of users, during which participants will ...

Match to trials
Find the right clinical trials for you in under a minute
Get started
Rate of Progression in USH2A-related Retinal Degeneration

Summary: The overall goal of this project funded by the Foundation Fighting Blindness is to characterize the natural history of disease progression in patients with USH2A related retinal degeneration associated with congenital hearing loss (Usher syndrome type 2a) or non-syndromic retinitis pigmentosa (RP39).

What are the Latest Advances for Amaurosis Fugax?
Keratoprostheses: Last Hope for the Most Severe Corneal Diseases.
Long-Term Anatomic and Visual Outcomes of Planned Preterm Delivery and Treatment of Norrie Disease.
Tired of the same old research?
Check Latest Advances
Outcomes and role of shunting during carotid endarterectomy for symptomatic patients.
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Amit M. Shelat, DO, FACP, FAAN, Attending Neurologist and Assistant Professor of Clinical Neurology, Renaissance School of Medicine at Stony Brook University, Stony Brook, NY. Review provided by VeriMed Healthcare Network. Also reviewed by David C. Dugdale, MD, Medical Director, Brenda Conaway, Editorial Director, and the A.D.A.M. Editorial team.

What are the references for this article ?

Biller J, Schneck MJ, Ruland S. Ischemic cerebrovascular disease. In: Jankovic J, Mazziotta JC, Pomeroy SL, Newman NJ, eds. Bradley and Daroff's Neurology in Clinical Practice. 8th ed. Philadelphia, PA: Elsevier; 2022:chap 65.

Brown GC, Sharma S, Brown MM. Ocular ischemic syndrome. In: Sadda SVR, Sarraf D, Freund KB, et al, eds. Ryan's Retina. 7th ed. Philadelphia, PA: Elsevier; 2023:chap 61.

Meschia JF, Bushnell C, Boden-Albala B, et al. Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014;45(12):3754-3832. PMID: 25355838 pubmed.ncbi.nlm.nih.gov/25355838/.